{"address1": "One Broadway", "address2": "14th Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "857 357 7000", "website": "https://www.nuvalent.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 142, "companyOfficers": [{"maxAge": 1, "name": "Dr. James R. Porter Ph.D.", "age": 48, "title": "CEO, President & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1053956, "exercisedValue": 0, "unexercisedValue": 97975576}, {"maxAge": 1, "name": "Prof. Matthew D. Shair Ph.D.", "age": 55, "title": "Founder, Head of Scientific Advisory Board & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 239000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Balcom CPA, M.B.A.", "age": 39, "title": "CFO & Treasurer", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 689410, "exercisedValue": 0, "unexercisedValue": 18132612}, {"maxAge": 1, "name": "Dr. Christopher D. Turner M.D.", "age": 55, "title": "Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 750970, "exercisedValue": 0, "unexercisedValue": 17545744}, {"maxAge": 1, "name": "Dr. Benjamin  Lane Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Henry  Pelish Ph.D.", "age": 51, "title": "Chief Scientific Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Deborah Ann Miller J.D., Ph.D.", "age": 48, "title": "Chief Legal Officer & Secretary", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 595959, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Metivier M.B.A.", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Darlene  Noci", "age": 46, "title": "Chief Development Officer", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Soglia Ph.D.", "title": "Senior Vice President of Translational Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 70.92, "open": 70.82, "dayLow": 67.8, "dayHigh": 72.59, "regularMarketPreviousClose": 70.92, "regularMarketOpen": 70.82, "regularMarketDayLow": 67.8, "regularMarketDayHigh": 72.59, "payoutRatio": 0.0, "beta": 1.419, "forwardPE": -16.037737, "volume": 1000323, "regularMarketVolume": 1000323, "averageVolume": 522675, "averageVolume10days": 538910, "averageDailyVolume10Day": 538910, "bid": 67.6, "ask": 68.39, "bidSize": 1, "askSize": 1, "marketCap": 4868657664, "fiftyTwoWeekLow": 61.795, "fiftyTwoWeekHigh": 113.51, "fiftyDayAverage": 78.2394, "twoHundredDayAverage": 84.53493, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3750356480, "profitMargins": 0.0, "floatShares": 40974058, "sharesOutstanding": 66162700, "sharesShort": 5490328, "sharesShortPriorMonth": 5472017, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0767, "heldPercentInsiders": 0.02895, "heldPercentInstitutions": 1.0801101, "shortRatio": 9.79, "shortPercentOfFloat": 0.2011, "impliedSharesOutstanding": 71597904, "bookValue": 14.995, "priceToBook": 4.534845, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -260756000, "trailingEps": -3.93, "forwardEps": -4.24, "52WeekChange": -0.08108109, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 68.0, "targetHighPrice": 137.0, "targetLowPrice": 100.0, "targetMeanPrice": 113.54545, "targetMedianPrice": 110.0, "recommendationKey": "none", "numberOfAnalystOpinions": 11, "totalCash": 1118301952, "totalCashPerShare": 15.619, "totalDebt": 0, "quickRatio": 20.702, "currentRatio": 20.963, "returnOnAssets": -0.187, "returnOnEquity": -0.29458, "freeCashflow": -100017000, "operatingCashflow": -185064000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "NUVL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Nuvalent, Inc.", "corporateActions": [], "preMarketTime": 1743595202, "regularMarketTime": 1743537601, "exchange": "NMS", "messageBoardId": "finmb_702442629", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyDayAverageChange": -10.239403, "fiftyDayAverageChangePercent": -0.13087271, "twoHundredDayAverageChange": -16.534927, "twoHundredDayAverageChangePercent": -0.19559877, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-29", "cryptoTradeable": false, "marketState": "PRE", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1627565400000, "preMarketChange": 5.0671997, "preMarketChangePercent": 7.451764, "preMarketPrice": 73.0672, "regularMarketChange": -2.9199982, "regularMarketDayRange": "67.8 - 72.59", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 522675, "fiftyTwoWeekLowChange": 6.205002, "fiftyTwoWeekLowChangePercent": 0.10041269, "fiftyTwoWeekRange": "61.795 - 113.51", "fiftyTwoWeekHighChange": -45.510002, "fiftyTwoWeekHighChangePercent": -0.40093386, "fiftyTwoWeekChangePercent": -8.108109, "epsTrailingTwelveMonths": -3.93, "epsForward": -4.24, "epsCurrentYear": -4.56472, "priceEpsCurrentYear": -14.896861, "longName": "Nuvalent, Inc.", "regularMarketChangePercent": -4.1173124, "regularMarketPrice": 68.0, "displayName": "Nuvalent", "trailingPegRatio": null}